Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 349 participants.

Also called NCT02467920

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 349 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02467920
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02467920. Randomized; no masking; primary purpose treatment. Start 2015-08 (actual); primary completion 2017-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
glargine + exenatide
Intervention (Drug)
aspart 30
Lead sponsor
Huazhong University of Science and Technology (class: other)

Record details

Record id
cardio:ct-nct02467920
Content hash
4fff259036b6ff561c0812821ab7f6eabf908efd4a43b12e121b4b73af2fed52